Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review

Liang, Xiaofeng; Liu, Bing; Chen, Jia-Cheng; Cao, Zhi; Chu, Frances; Xiong, Lin; Wang, Shengzhong; Wu, Jincai

doi:10.3389/fonc.2023.1177466

Cited by 9 publications

(2 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One potential drug tolerance strategy adopted by tumor cells is the modification of their own cell cycle ( 42 ). On this light, NCI-H835 cell line showed no cell cycle arrest, whereas both NCI-H727 and UMC-11 cell lines showed cell cycle arrest in the G 2 /M phase.…”

Section: Discussionmentioning

confidence: 99%

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Oldani,

Cantone,

Gaudenzi

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

IntroductionLung carcinoids (LCs) are a type of neuroendocrine tumor (NET) that originate in the bronchopulmonary tract. LCs account for 20–25% of all NETs and approximately 1–2% of lung cancers. Given the highly vascularized nature of NETs and their tendency to overexpress vascular growth factor receptors (VEGFR), inhibiting angiogenesis appears as a potential therapeutic target in slowing down tumor growth and spread. This study evaluated the long-term antitumor activity and related mechanisms of axitinib (AXI), a VEGFR-targeting drug, in LC cell lines.MethodsThree LC cell lines (NCI-H727, UMC-11 and NCI-H835) were incubated with their respective EC50 AXI concentrations for 6 days. At the end of the incubation, FACS experiments and Western blot analyses were performed to examine changes in the cell cycle and the activation of apoptosis. Microscopy analyses were added to describe the mechanisms of senescence and mitotic catastrophe when present.ResultsThe primary effect of AXI on LC cell lines is to arrest tumor growth through an indirect DNA damage. Notably, AXI triggers this response in diverse manners among the cell lines, such as inducing senescence or mitotic catastrophe. The drug seems to lose its efficacy when the DNA damage is mitigated, as observed in NCI-H835 cells.ConclusionThe ability of AXI to affect cell viability and proliferation in LC tumor cells highlights its potential as a therapeutic agent. The role of DNA damage and the consequent activation of senescence seem to be a prerequisite for AXI to exert its function.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Oldani,

Cantone,

Gaudenzi

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…In fact, it is now clear that phenotypic plasticity and non-genetic mechanisms are not only critical but are also leveraged as a bet-hedging strategy in cancer [ 47 , 66 , 67 , 68 , 69 ]. Furthermore, the realization that phenotypic plasticity and non-genetic mechanisms can also account for a “persister” population contributing to drug resistance in cancer further underscores their importance in the disease pathology [ 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ].…”

Section: Phenotypic Plasticity Non-genetic Phenotypic Heterogeneity A...mentioning

confidence: 99%

Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

Ramisetty,

Subbalakshmi,

Pareek

et al. 2024

JCM

View full text Add to dashboard Cite

Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a fitness advantage to the cancer cell by altering its phenotype to suit environmental circumstances. Until recently, new traits, especially in cancer, were thought to arise due to genetic factors; however, it is now amply evident that such traits could also emerge non-genetically due to phenotypic plasticity. Furthermore, phenotypic plasticity of cancer cells contributes to phenotypic heterogeneity in the population, which is a major impediment in treating the disease. Finally, plasticity also impacts the group behavior of cancer cells, since competition and cooperation among multiple clonal groups within the population and the interactions they have with the tumor microenvironment also contribute to the evolution of drug resistance. Thus, understanding the mechanisms that cancer cells exploit to tailor their phenotypes at a systems level can aid the development of novel cancer therapeutics and treatment strategies. Here, we present our perspective on a team medicine-based approach to gain a deeper understanding of the phenomenon to develop new therapeutic strategies.

show abstract

Investigate the relationship between Bacillus coagulans and its inhibition of chemotherapy‐induced lung cancer resistance

Ting,

Wang,

Liao

et al. 2024

Biotech and App Biochem

View full text Add to dashboard Cite

Lung cancer is a leading cause of death globally, with lung adenocarcinoma being the most common subtype. Despite advancements in targeted therapy, drug resistance remains a major challenge. This study investigated the impact of Bacillus coagulans on drug resistance in lung adenocarcinoma cells. The cells were pretreated with B. coagulans culture filtrate (BCCF), and functional assays were performed, including cell proliferation, cell cycle, apoptosis, and immunofluorescence staining. Results showed that BCCF induced cell cycle arrest at the S phase, reducing cell proliferation and suppressing drug resistance marker P‐glycoprotein expression in BCCF‐treated resistant cells rather than BCCF‐treated control cells. Moreover, drug‐resistant cells exhibited the ability for epithelial‐mesenchymal transition, which could contribute to their necrosis through the iron‐mediated cell death pathway upon BCCF treatment. Proteomic analysis identified downregulation of DNA mismatch repair protein PMS2 after BCCF treatment. These findings suggest that B. coagulans may modulate the DNA repair pathway, influencing drug resistance in lung adenocarcinoma cells. In conclusion, this study highlights the potential impact of B. coagulans on drug‐resistant lung adenocarcinoma cells. Further investigation and understanding of the regulatory mechanisms by which B. coagulans modulates drug resistance in lung adenocarcinoma can aid in the development of more effective treatment strategies to improve the prognosis of lung cancer patients.

show abstract

Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review

Cited by 9 publications

References 115 publications

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

Investigate the relationship between Bacillus coagulans and its inhibition of chemotherapy‐induced lung cancer resistance

Contact Info

Product

Resources

About